Systemic Therapy for Advanced Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer: ASCO Guideline Update

Use of Biosimilar Medications in Oncology

(2022) Zeina Nahleh et al.   JCO Oncology Practice

Trastuzumab Deruxtecan versus Trastuzumab Emtansine for Breast Cancer

(2022) Javier Cortés et al.   NEW ENGLAND JOURNAL OF MEDICINE

Efficacy of Margetuximab vs Trastuzumab in Patients With Pretreated ERBB2-Positive Advanced Breast Cancer

(2021) Hope S. Rugo et al.   JAMA Oncology

Pyrotinib plus capecitabine versus lapatinib plus capecitabine for the treatment of HER2-positive metastatic breast cancer (PHOEBE): a multicentre, open-label, randomised, controlled, phase 3 trial

(2021) Binghe Xu et al.   LANCET ONCOLOGY

Intracranial Efficacy and Survival With Tucatinib Plus Trastuzumab and Capecitabine for Previously Treated HER2-Positive Breast Cancer With Brain Metastases in the HER2CLIMB Trial

(2020) Nancy U. Lin et al.   JOURNAL OF CLINICAL ONCOLOGY

Guideline-Concordant Treatment Among Elderly Women With HER2-Positive Metastatic Breast Cancer in the United States

(2020) Ami M. Vyas et al.   Journal of the National Comprehensive Cancer Network

Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study

(2020) Sandra M Swain et al.   LANCET ONCOLOGY

Abemaciclib plus trastuzumab with or without fulvestrant versus trastuzumab plus standard-of-care chemotherapy in women with hormone receptor-positive, HER2-positive advanced breast cancer (monarcHER): a randomised, open-label, phase 2 trial

(2020) Sara M Tolaney et al.   LANCET ONCOLOGY

Cancer Disparities and Health Equity: A Policy Statement From the American Society of Clinical Oncology

(2020) Manali I. Patel et al.   JOURNAL OF CLINICAL ONCOLOGY

Neratinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in HER2-Positive Metastatic Breast Cancer Previously Treated With ≥ 2 HER2-Directed Regimens: Phase III NALA Trial

(2020) Cristina Saura et al.   JOURNAL OF CLINICAL ONCOLOGY

Trastuzumab emtansine plus atezolizumab versus trastuzumab emtansine plus placebo in previously treated, HER2-positive advanced breast cancer (KATE2): a phase 2, multicentre, randomised, double-blind trial

(2020) Leisha A Emens et al.   LANCET ONCOLOGY

Fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection plus chemotherapy in HER2-positive early breast cancer (FeDeriCa): a randomised, open-label, multicentre, non-inferiority, phase 3 study

(2020) Antoinette R Tan et al.   LANCET ONCOLOGY

Safety of trastuzumab emtansine (T-DM1) in patients with HER2-positive advanced breast cancer: Primary results from the KAMILLA study cohort 1

(2019) Filippo Montemurro et al.   EUROPEAN JOURNAL OF CANCER

Results From the First Multicenter, Open-label, Phase IIIb Study Investigating the Combination of Pertuzumab With Subcutaneous Trastuzumab and a Taxane in Patients With HER2-positive Metastatic Breast Cancer (SAPPHIRE)

(2019) Natasha Woodward et al.   Clinical Breast Cancer

Preliminary safety and efficacy of first-line pertuzumab combined with trastuzumab and taxane therapy for HER2-positive locally recurrent or metastatic breast cancer (PERUSE)

(2019) T Bachelot et al.   ANNALS OF ONCOLOGY

Trastuzumab emtansine with or without pertuzumab versus trastuzumab with taxane for human epidermal growth factor receptor 2–positive advanced breast cancer: Final results from MARIANNE

(2019) Edith A. Perez et al.   CANCER

Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer

(2019) Rashmi K. Murthy et al.   NEW ENGLAND JOURNAL OF MEDICINE

Trastuzumab Deruxtecan in Previously Treated HER2-Positive Breast Cancer

(2019) Shanu Modi et al.   NEW ENGLAND JOURNAL OF MEDICINE

Systemic Therapy for Patients With Advanced Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer: ASCO Clinical Practice Guideline Update

(2018) Sharon H. Giordano et al.   JOURNAL OF CLINICAL ONCOLOGY

Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Focused Update

(2018) Antonio C. Wolff et al.   JOURNAL OF CLINICAL ONCOLOGY

PF-05280014 (a trastuzumab biosimilar) plus paclitaxel compared with reference trastuzumab plus paclitaxel for HER2-positive metastatic breast cancer: a randomised, double-blind study

(2018) Mark D. Pegram et al.   BRITISH JOURNAL OF CANCER

Effect of a Proposed Trastuzumab Biosimilar Compared With Trastuzumab on Overall Response Rate in Patients With ERBB2 (HER2)–Positive Metastatic Breast Cancer

(2017) Hope S. Rugo et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Patient-Clinician Communication: American Society of Clinical Oncology Consensus Guideline

(2017) Timothy Gilligan et al.   JOURNAL OF CLINICAL ONCOLOGY

Randomized Phase III Trial of Trastuzumab Plus Capecitabine With or Without Pertuzumab in Patients With Human Epidermal Growth Factor Receptor 2–Positive Metastatic Breast Cancer Who Experienced Disease Progression During or After Trastuzumab-Based Therapy

(2017) Ander Urruticoechea et al.   JOURNAL OF CLINICAL ONCOLOGY

Integration of Palliative Care Into Standard Oncology Care: American Society of Clinical Oncology Clinical Practice Guideline Update

(2017) Betty R. Ferrell et al.   JOURNAL OF CLINICAL ONCOLOGY

Trastuzumab emtansine versus capecitabine plus lapatinib in patients with previously treated HER2-positive advanced breast cancer (EMILIA): a descriptive analysis of final overall survival results from a randomised, open-label, phase 3 trial

(2017) Véronique Diéras et al.   LANCET ONCOLOGY

Trastuzumab emtansine versus treatment of physician's choice in patients with previously treated HER2-positive metastatic breast cancer (TH3RESA): final overall survival results from a randomised open-label phase 3 trial

(2017) Ian E Krop et al.   LANCET ONCOLOGY

Do all patients with advanced HER2 positive breast cancer need upfront-chemo when receiving trastuzumab? Randomized Phase III trial SAKK 22/99

(2016) O. Pagani et al.   ANNALS OF ONCOLOGY

Updating the American Society of Clinical Oncology Value Framework: Revisions and Reflections in Response to Comments Received

(2016) Lowell E. Schnipper et al.   JOURNAL OF CLINICAL ONCOLOGY

Neratinib Plus Paclitaxel vs Trastuzumab Plus Paclitaxel in Previously Untreated Metastatic ERBB2-Positive Breast Cancer

(2016) Ahmad Awada et al.   JAMA Oncology

American Society of Clinical Oncology Statement: A Conceptual Framework to Assess the Value of Cancer Treatment Options

(2015) Lowell E. Schnipper et al.   JOURNAL OF CLINICAL ONCOLOGY

Systemic Therapy for Patients With Advanced Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline

(2014) Sharon H. Giordano et al.   JOURNAL OF CLINICAL ONCOLOGY

Cost Sharing and Adherence to Tyrosine Kinase Inhibitors for Patients With Chronic Myeloid Leukemia

(2013) Stacie B. Dusetzina et al.   JOURNAL OF CLINICAL ONCOLOGY

GRADE guidelines: 3. Rating the quality of evidence

(2011) Howard Balshem et al.   JOURNAL OF CLINICAL EPIDEMIOLOGY

Building better guidelines with BRIDGE-Wiz: development and evaluation of a software assistant to promote clarity, transparency, and implementability

(2011) Richard N Shiffman et al.   JOURNAL OF THE AMERICAN MEDICAL INFORMATICS ASSOCIATION

Patient and Plan Characteristics Affecting Abandonment of Oral Oncolytic Prescriptions

(2011) Sonya Blesser Streeter et al.   Journal of Oncology Practice

American Society of Clinical Oncology Guidance Statement: The Cost of Cancer Care

(2009) Neal J. Meropol et al.   JOURNAL OF CLINICAL ONCOLOGY